<DOC>
	<DOCNO>NCT00306644</DOCNO>
	<brief_summary>The study investigate effect rosiglitazone placebo carotid intima medium thickness patient insulin resistance syndrome and/or type 2 diabetes .</brief_summary>
	<brief_title>Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes</brief_title>
	<detailed_description>RAS Rosiglitazone Atherosclerosis Study : A 1 year randomise , double-blind , parallel group , placebo control study evaluate efficacy rosiglitazone progression intima-media thickness carotid artery subject insulin resistance syndrome and/or type 2 diabetes mellitus</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : insulin resistant syndrome Type 2 Diabetes . Exclusion criterion : Use &gt; = 2 concomitant oral antihyperglycaemic agent within 3 month study start . Initiation antihypertensive lipid lower therapy &lt; = 6 month prior study start increase dose 3 month prior study start . Unstable severe angina congestive heart failure NYHA class iiv , history acute myocardial infarction stroke within last 6 month . Any history surgical intervention right carotid artery . Clinically significant hepatic disease . Creatinine clearance &lt; 40ml/min .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>intima medium thickness</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>